 SAN DIEGO, July 21, 2021 GLOBE NEWSWIRE -- TRACON Pharmaceuticals NASDAQ: TCON TRACON or the Company, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics, today announced that it has entered into an underwriting agreement with H.C. Wainwright Co. under which the underwriter has agreed to purchase on a firm commitment basis 2,617,802 shares of the Companys common stock at a public offering price of 3.82 per share, less underwriting discounts and commissions. In addition, the Company has granted the underwriter a 30-day option to purchase up to an additional 392,670 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 26, 2021, subject to satisfaction of customary closing conditions. 